Skip to main content
VRCA
NASDAQ Life Sciences

Verrica Q3 Revenue Up 58% to $5.7M; Runway Extended Into Q4 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.71
Mkt Cap
$63.905M
52W Low
$3.08
52W High
$9.821
52W Position info
20% above low
Off High info
62% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

VRCA sits 20% above its 52-week low of $3.08.

Summary

Verrica posted record Q3 YCANTH revenue of $5.7 million, up 57.9% year over year, and said full access to its $27.5 million credit facility extends cash runway into Q4 2027, past both common-warts Phase 3 readouts.


Key Events · Earnings and Guidance · VRCA

  • Record Q3 YCANTH Revenue

    U.S. YCANTH net product revenue was $5.7 million, up 11.9% sequentially and 57.9% year over year; total revenue was $6.9 million versus $14.3 million a year ago, which included a $10.0 million one-time Torii milestone.

  • Runway Extended Into Q4 2027

    The company unlocked the remaining $15.0 million of its $27.5 million credit facility with an entity controlled by Chairman Paul B. Manning, and now says liquidity funds operations through data readouts for both common-warts trials.

  • Loss Widened on Phase 3 Costs

    Net loss was $12.4 million, or $0.58 per share, versus $0.3 million a year ago; R&D rose to $7.6 million from $2.2 million, including $3.7 million of non-cash Phase 3 costs funded by Torii.

  • Balance Sheet Still Thin

    Cash was $14.4 million at September 30, 2026, down from $30.1 million at year-end 2025, and total stockholders' equity was a $6.0 million deficit.


Analysis · VRCA · Life Sciences

YCANTH net product revenue hit a record $5.7 million, up 57.9% year over year, and the company says it now has funding through both common-warts Phase 3 readouts after unlocking the remaining $15.0 million of its $27.5 million credit facility. That matters because the last 10-Q carried a going-concern warning; the runway statement pushes the financing question out to late 2027. The offset is that the quarter still lost $12.4 million and the balance sheet shows a $6.0 million stockholders' deficit, so the improvement is operating momentum rather than profitability.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VRCA was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.9M. The 52-week trading range was $3.08 to $9.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VRCA - Latest Insights

VRCA
Nov 12, 2026, 4:16 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $3.71 info
Change: $0 (0%) info
Market Cap: $63.905M info
VRCA
Aug 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.76
Real-time Price: $3.71 info
Change: -$1.05 (-22%) info
Market Cap: $63.905M info
VRCA
Aug 18, 2026, 5:00 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $4.68
Real-time Price: $3.71 info
Change: -$0.970 (-21%) info
Market Cap: $63.905M info
VRCA
Aug 06, 2026, 4:37 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.36
Real-time Price: $3.71 info
Change: -$1.65 (-31%) info
Market Cap: $63.905M info
VRCA
Aug 06, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.36
Real-time Price: $3.71 info
Change: -$1.65 (-31%) info
Market Cap: $63.905M info